TRCT
ELAB icon

Tower Research Capital (TRC)’s Elevai Labs ELAB Stock Holding History

Tower Research Capital (TRC)’s Portfolio ELAB Stock Details ELAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03K Buy
251
+238
+1,831% +$6.03K ﹤0.01% 4585
2026
Q1 		$773 Hold
13
– – ﹤0.01% 4780
2025
Q4 		$4.64K Buy
13
+11
+550% +$13.1K ﹤0.01% 4196
2025
Q3 		$2.45K Buy
2
+1
+100% +$1.6K ﹤0.01% 4627
2025
Q2 		$1.62K Hold
1
– – ﹤0.01% 4771
2025
Q1 		$5.54K Buy
+1
New +$8.79K ﹤0.01% 4114
2024
Q4 		– Hold
0
– – – 5139
2024
Q3 		– Hold
0
– – – 4876

Other funds holding ELAB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tower Research Capital (TRC)'s ELAB Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Elevai Labs (ELAB) stake by 1,831% in Q2 2026, buying an estimated $6.03K and bringing the position to 251 shares worth $3.03K. The position accounts for ﹤0.01% of the portfolio, ranked #4585.

Tower Research Capital (TRC) first reported a position in ELAB in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.54K in Q1 2025. 11 funds tracked by Wall St. Rank hold ELAB as of Q2 2026.

  • Tower Research Capital (TRC) held 251 shares of Elevai Labs worth $3.03K as of Q2 2026.
  • Tower Research Capital (TRC) bought 238 Elevai Labs shares in Q2 2026, an estimated $6.03K.
  • Elevai Labs made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4585 holding.
  • Tower Research Capital (TRC) first reported a position in Elevai Labs in Q1 2025 and has held it in 6 quarters since.
  • Tower Research Capital (TRC)'s Elevai Labs position peaked at $5.54K in Q1 2025.
  • 11 funds tracked by Wall St. Rank held Elevai Labs as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.